Доступ предоставлен для: Guest
Портал Begell Электронная Бибилиотека e-Книги Журналы Справочники и Сборники статей Коллекции
Forum on Immunopathological Diseases and Therapeutics
SJR: 0.309 SNIP: 0.041 CiteScore™: 0.18

ISSN Печать: 2151-8017
ISSN Онлайн: 2151-8025

Archives: Volume 1, 2010 to Volume 7, 2016

Forum on Immunopathological Diseases and Therapeutics

DOI: 10.1615/ForumImmunDisTher.2014008368
pages 219-239

Bacterial Toxins in Cancer Immunotherapy

Irena Adkins
Sotio a.s., Prague, Czech Republic; and Department of Immunology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic
Lenka Sadilkova
Sotio a.s., Prague, Czech Republic; and Department of Immunology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic
Lenka Palova-Jelinkova
Sotio a.s., Prague, Czech Republic; and Department of Immunology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic

Краткое описание

Bacterial protein toxins perfected through evolution in pathogenic bacteria play an important role in infectious diseases and share the ability to target various intracellular proteins to modulate host immune responses. Several bacterial toxins and their nontoxic mutants have been intensively studied over the past decades to harness their abilities to enter host cells and deliver drugs for a direct elimination of cancer cells, to carry antigenic epitopes to stimulate adaptive T cell responses, and to boost immunity as adjuvants. Some of these toxins may be utilized in the diagnostics of cancer. Whereas the immunotherapeutic potential of some bacterial toxins is currently being evaluated in various phases of clinical cancer trials, the medical use of others needs to be further established. The major achievement in toxin-targeted immunotherapy is a derivative of lipopolysaccharide monophosphoryl lipid A, muramyl dipeptide derivative Mifamurtide, and Corynebacterium diphtheriae diphtheria toxin-based immunotoxin denileukin diftitox. However, some limitations of the use of bacterial toxins in human immunotherapy remain to be overcome.


Articles with similar content:

DNA Vaccines
Critical Reviews™ in Immunology, Vol.18, 1998, issue 5
Wayne C. Lai, Michael Bennett
Microparticles and Nanoparticles as Delivery Systems for DNA Vaccines
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.20, 2003, issue 2&3
Zhengrong Cui, Russell J. Mumper
Photosensitized Inactivation of Protozoa Pathogenic Agents of Water- and Vector-Borne Diseases
Forum on Immunopathological Diseases and Therapeutics, Vol.2, 2011, issue 3
Laura Guidolin, Clara Fabris, Marina Soncin, Giulio Jori, Olimpia Coppellotti
Victory and Defeat in the Induction of a Therapeutic Response through Vaccine Therapy for Human and Canine Brain Tumors: A Review of the State of the Art
Critical Reviews™ in Immunology, Vol.34, 2014, issue 5
Nate N. Waldron , G Elizabeth Pluhar, Rob Shaver, Brian M. Andersen, Michael R. Olin, Christopher L. Moertel
Structuring Polymers for Delivery of DNA-Based Therapeutics: Updated Insights
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.29, 2012, issue 6
Suresh P. Vyas, Shailja Tiwari, Madhu Gupta